Skip to main content
. Author manuscript; available in PMC: 2017 May 25.
Published in final edited form as: J Vitreoretin Dis. 2017 Jan 26;1(1):65–74. doi: 10.1177/2474126416683299

Figure 2.

Figure 2

Patient 2 is an 67 year-old phakic Caucasian man with active neovascular AMD with subfoveal choroidal neovascularization (A, B). Patient had significant intra-retinal fluid with exudate on OCT (C) and underwent intravitreal injection of ranibizumab with minimal response (D) after 1 month. He subsequently received another injection of bevacizumab, but with a similar lack of effect (E) after 1 month. At that time, the eye was treated with a combined injection of intravitreal bevacizumab and the dexamethasone intravitreal implant after which there was a significant decrease in intraretinal fluid and improvement of visual acuity to 20/70 after 1 month (F). There was no elevation of IOP or injection-related complications.